IL28BPolymorphism Does Not Determine Outcomes of Hepatitis B Virus or HIV Infection | Zendy

Maureen P. Martin | Zendy; Qi Ying | Zendy; James J. Goedert | Zendy; Shehnaz K. Hussain | Zendy; Gregory D. Kirk | Zendy; W. Keith Hoots | Zendy; Susan Buchbinder | Zendy; Mary Carrington | Zendy; Chloe L. Thio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

IL28BPolymorphism Does Not Determine Outcomes of Hepatitis B Virus or HIV Infection

Author(s) -

Maureen P. Martin,

Qi Ying,

James J. Goedert,

Shehnaz K. Hussain,

Gregory D. Kirk,

W. Keith Hoots,

Susan Buchbinder,

Mary Carrington,

Chloe L. Thio

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/657146

Subject(s) - hepatitis b virus , hepatitis c virus , virology , odds ratio , interleukin 28b , haplotype , immunology , genotype , hepatitis b , virus , biology , medicine , ribavirin , gene , genetics

An IL28B haplotype strongly determines the outcome of natural and interferon-α treated hepatitis C virus (HCV) infection. To assess whether the polymorphism marking the haplotype (rs12979860) also affects other interferon-α responsive chronic viral illnesses, namely hepatitis B virus (HBV) and human immunodeficiency virus (HIV) type 1 infections, we genotyped 226 individuals with HBV persistence, 384 with HBV recovery, and 2548 with or at high risk for HIV infection. The C/C genotype of rs12979860 was not associated with HBV recovery (odds ratio, 0.99), resistance to HIV infection (odds ratio, 0.97), or HIV disease progression (P > .05). This IL28B single-nucleotide polymorphism affects the immune response to HCV but not to HBV or HIV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research